NBW Capital LLC Has $3.83 Million Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

NBW Capital LLC lifted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 25.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 43,886 shares of the biotechnology company’s stock after purchasing an additional 8,821 shares during the quarter. NBW Capital LLC owned about 0.07% of Blueprint Medicines worth $3,828,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BPMC. Quarry LP acquired a new position in Blueprint Medicines during the 3rd quarter worth approximately $32,000. R Squared Ltd acquired a new position in Blueprint Medicines during the 4th quarter worth approximately $51,000. Covestor Ltd boosted its position in Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in Blueprint Medicines during the 4th quarter worth approximately $88,000. Finally, Van ECK Associates Corp boosted its position in Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 363 shares during the last quarter.

Analyst Upgrades and Downgrades

BPMC has been the subject of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a research note on Thursday, February 13th. Finally, Wedbush reiterated an “outperform” rating and set a $128.00 price objective on shares of Blueprint Medicines in a research note on Friday. Two analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $123.83.

Blueprint Medicines Stock Down 7.1 %

BPMC stock opened at $89.75 on Tuesday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock has a market capitalization of $5.74 billion, a price-to-earnings ratio of -83.10 and a beta of 0.62. The business’s fifty day moving average price is $99.52 and its two-hundred day moving average price is $94.37. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, equities analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insider Transactions at Blueprint Medicines

In other news, insider Ariel Hurley sold 1,819 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the sale, the director now directly owns 152,396 shares in the company, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,224 shares of company stock valued at $4,541,139. 4.21% of the stock is owned by corporate insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.